Cash Flow from Financial Activities: The net amount of cash transactions used in funding activities.
Myriad Genetics, Inc. (MYGN) had Cash Flow from Financial Activities of $-7.40M for the most recently reported fiscal year, ending 2024-12-31.
| Income Statement Financials | |
$837.60M |
|
$-127.30M |
|
$252.20M |
|
$585.40M |
|
$961.10M |
|
$-123.50M |
|
$0.00M |
|
$-123.50M |
|
$-123.50M |
|
$-127.30M |
|
$-127.30M |
|
$-127.30M |
|
$-127.30M |
|
$-123.50M |
|
$-5.70M |
|
90.60M |
|
90.60M |
|
$-1.41 |
|
$-1.41 |
|
| Balance Sheet Financials | |
$298.00M |
|
$117.40M |
|
$729.60M |
|
$1.03B |
|
$164.10M |
|
$39.60M |
|
$162.40M |
|
$326.50M |
|
$701.10M |
|
$152.40M |
|
$701.10M |
|
91.30M |
|
| Cash Flow Statement Financials | |
$-8.70M |
|
$-11.90M |
|
|
Cash Flow from Financial Activities |
$-7.40M |
$140.90M |
|
$111.90M |
|
$-29.00M |
|
$49.80M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
1.82 |
|
-- |
|
-- |
|
0.05 |
|
0.06 |
|
69.89% |
|
-14.74% |
|
-14.74% |
|
-0.68% |
|
-14.74% |
|
-15.20% |
|
$-27.70M |
|
-- |
|
-- |
|
-- |
|
0.82 |
|
9.17 |
|
6.91 |
|
52.82 |
|
-18.16% |
|
-83.53% |
|
-12.39% |
|
-17.19% |
|
$7.68 |
|
$-0.31 |
|
$-0.10 |
|